Edge Therapeutics Inc (EDGE) was Resumed by Leerink Partners to “Outperform” and the brokerage firm has set the Price Target at $21. Leerink Partners advised their Clients and Investors in a research report released on Mar 3, 2017.

Based on several research reports , Leerink Partners Resumed Edge Therapeutics Inc on Mar 3, 2017 to “Outperform”, Price Target of the shares are set at $21.Leerink Partners Resumed Edge Therapeutics Inc on Mar 3, 2017 to “Outperform”, Price Target of the shares are set at $21.

Several company insiders have filed Insider transactions , on Feb 8, 2017, Brian A Leuthner (President and CEO) sold 1,500 shares at $9.52 per share price. According to the SEC, on Aug 9, 2016, W Bradford Middlekauff (Senior VP, GC and Secretary) purchased 10,000 shares at $9.45 per share price. On Mar 15, 2016, James Healy (director) purchased 541,343 shares at $7.30 per share price, according to the Form-4 filing with the securities and exchange commission.

Edge Therapeutics Inc closed down -0.1 points or -0.99% at $9.99 with 67,693 shares getting traded on Monday. Post opening the session at $10.04, the shares hit an intraday low of $9.8474 and an intraday high of $10.17 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Edge Therapeutics Inc. is a United States-based biotechnology company which focuses on developing therapies in the management of acute life-threatening neurological conditions. The Company offers Precisa a programmable biodegradable polymer-based development platform. Its product candidates include EG-1962 which completed Phase I/II clinical trial and EG-1964. Its EG-1962 is a polymer-based micro particle containing nimodipine that helps in managing patient outcomes after aneurysmal subarachnoid hemorrhage. Its EG-1964 is used as prophylactic treatment in the management of chronic subdural hematoma (cSDH) to prevent recurrent bleeding on surface of the brain. Its product candidates utilize Precisa which allows it to create therapeutics based on specific physical and chemical properties. Its Precisa enables targeted delivery to the exact site of the injury and provides a controlled drug release to the affected area. It is also developing other product candidate EG-1963.

Edge Therapeutics Inc

Read Full Article